Clinical value of whole body fluorine‐18 fluorodeoxyglucose positron emission tomography/computed tomography in the detection of metastatic bladder cancer

Objectives: To investigate the value of whole‐body fluorine‐18 2‐fluoro‐2‐deoxy‐D‐glucose positron emission tomography/computed tomography for the detection of metastatic bladder cancer. Methods: From December 2006 to August 2010, 60 bladder cancer patients (median age 60.5 years old, range 32–96) underwent whole body positron emission tomography/computed tomography positron emission tomography/computed tomography. The diagnostic accuracy was assessed by performing both organ‐based and patient‐based analyses. Identified lesions were further studied by biopsy or clinically followed for at least 6 months. Results: One hundred and thirty‐four suspicious lesions were identified. Among them, 4 primary cancers (2 pancreatic cancers, 1 colonic and 1 nasopharyngeal cancer) were incidentally detected, and the patients could be treated on time. For the remaining 130 lesions, positron emission tomography/computed tomography detected 118 true positive lesions (sensitivity = 95.9%). On the patient‐based analysis, the overall sensitivity and specificity resulted to be 87.1% and 89.7%, respectively. There was no difference of sensitivity and specificity in patients with or without adjuvant treatment in terms of detection of metastatic sites by positron emission tomography/computed tomography. Compared with conventional imaging modality, positron emission tomography/computed tomography correctly changed the management in 15 patients (25.0%). Conclusions: Positron emission tomography/computed tomography has excellent sensitivity and specificity in the detection of metastatic bladder cancer and it provides additional diagnostic information compared to standard imaging techniques.     

The role of positron emission tomography in the management of colorectal cancer

Positron emission tomography (PET) is a functional imaging modality that has made the transition from the research enviroment to the clinical enviroment over the last 10 years. Its major role is in the field of oncology where it is being used increasingly in the management of several tumour types including colorectal cancer. This review aims to outline the current and future role of PET scanning in the field of colorectal cancer.     

High-resolution fluorodeoxyglucose positron emission tomography with compression ("positron emission mammography") is highly accurate in depicting primary breast cancer

We sought to prospectively assess the diagnostic performance of a high-resolution positron emission tomography (PET) scanner using mild breast compression (positron emission mammography [PEM]). Data were collected on concomitant medical conditions to assess potential confounding factors. At four centers, 94 consecutive women with known breast cancer or suspicious breast lesions received 18F-fluorodeoxyglucose (FDG) intravenously, followed by PEM scans. Readers were provided clinical histories and x-ray mammograms (when available). After excluding inevaluable cases and two cases of lymphoma, PEM readings were correlated with histopathology for 92 lesions in 77 women: 77 index lesions (42 malignant), 3 ipsilateral lesions (3 malignant), and 12 contralateral lesions (3 malignant). Of 48 cancers, 16 (33%) were clinically evident; 11 (23%) were ductal carcinoma in situ (DCIS), and 37 (77%) were invasive (30 ductal, 4 lobular, and 3 mixed; median size 21 mm). PEM depicted 10 of 11 (91%) DCIS and 33 of 37 (89%) invasive cancers. PEM was positive in 1 of 2 T1a tumors, 4 of 6 T1b tumors, 7 of 7 T1c tumors, and 4 of 4 cases where tumor size was not available (e.g., no surgical follow-up). PEM sensitivity for detecting cancer was 90%, specificity 86%, positive predictive value (PPV) 88%, negative predictive value (NPV) 88%, accuracy 88%, and area under the receiver-operating characteristic curve (Az) 0.918. In three patients, cancer foci were identified only on PEM, significantly changing patient management. Excluding eight diabetic subjects and eight subjects whose lesions were characterized as clearly benign with conventional imaging, PEM sensitivity was 91%, specificity 93%, PPV 95%, NPV 88%, accuracy 92%, and Az 0.949 when interpreted with mammographic and clinical findings. FDG PEM has high diagnostic accuracy for breast lesions, including DCIS.     

Brain responses during the first desire to void: A positron emission tomography study

Objectives:   First desire to void (FDV) is defined as the first feeling that would lead the patient to pass urine. The aim of the present study is to identify the brain regions activated during FDV.
Methods:   Six healthy right-handed male volunteers, aged 31–40 years, agreed to participate in this study. Rather than inserting a urethral catheter, we used a urinary volume monitoring unit and a self-adhesive external condom catheter for this study. Positron emission tomography (PET) scans obtained in the FDV and post-voiding (absence of urge to void) (REST) states were analyzed and compared.
Results:   First desire to void state was associated with increased blood flow in the right and left cerebellum, right parahippocampal gyrus (Brodmann area [BA] 30), left superior frontal gyrus (BA9), and left cingulate gyrus (BA32). Rest state was associated with decreased blood flow in the right superior temporal gyrus (BA22), right uncus (BA28), right cingulate gyrus (BA32), left middle temporal gyrus (BA21), and left medial frontal gyrus (BA25). According to region of interest analysis, regional cerebral blood flow of the periaqueductal grey and pons was significantly increased at FDV as opposed to REST.
Conclusions:   We located possible brain activity associated with the FDV sensation. Combined activation of the right and left cerebellum, parahippocampal gyrus, superior frontal gyrus, and left cingulate gyrus could be associated with FDV.     

Update on positron emission tomography for imaging of prostate cancer

Prostate cancer is the most common non‐cutaneous malignancy among men in the Western world, and continues to be a major health problem. Imaging has recently become more important in the clinical management of prostate cancer patients, including diagnosis, staging, choice of optimal treatment strategy, treatment follow up and restaging. Positron emission tomography, a functional and molecular imaging technique, has opened a new field in clinical oncological imaging. The most common positron emission tomography radiotracer, ¹⁸F‐fluorodeoxyglucose, has been limited in imaging of prostate cancer. Recently, however, other positron emission tomography tracers, such as ¹¹C‐acetate and ¹¹C‐ or ¹⁸F‐choline, have shown promising results. In the present review article, we overview the potential and current use of positron emission tomography or positron emission tomography/computed tomography imaging employing the four most commonly used positron emission tomography radiotracers, ¹⁸F‐fluorodeoxyglucose, ¹¹C‐acetate and ¹¹C‐ or ¹⁸F‐choline, for imaging evaluation of prostate cancer.     

Application of whole-body positron emission tomography in the imaging of esophageal cancer: Report of a case

We describe herein a case of esophageal cancer in which both primary and metastatic lymph node foci were successfully imaged with whole-body positron emission tomography (PET) scanning. A 75-year-old woman with biopsy-proven squamous cell carcinoma of the esophagus underwent whole-body PET scanning for staging evaluation. The patient was injected with 373.7 MBq [¹⁸F]-2-fluoro-2-d-deoxyglucose (FDG), and 60 min later, scanning was performed from the neck to the pelvis. The whole-body images showed intense FDG uptake in the primary lesion and multiple focal areas of increased FDG uptake in the mediastinum and abdomen, which corresponded to the lymph node foci confirmed by computed tomography (CT) scan. To our knowledge, this is the first report of whole-body PET scanning being applied in the imaging of esophageal cancer.     

The value of FDG positron emission tomography in the management of patients with breast cancer

Increasing experience with positron emission tomography (PET) scanning in breast cancer patients is revealing a significant role for this imaging modality. This report summarizes the experience of 2-[F18]fluoro-2-deoxy-D-glucose (FDG) PET scanning in 165 breast cancer patients from the BC Cancer Agency, British Columbia, Canada, and reviews the literature on this topic. Using the database at PETSCAN Vancouver, we identified imaged patients with a diagnosis of breast cancer. We then conducted a retrospective review of these patients' BC Cancer Agency charts to extract demographic and follow-up information. Between November 2000 and March 2003 we identified 165 patients with histologically confirmed breast cancer who had undergone PET scanning, were registered at the BC Cancer Agency, and had follow-up information. The median patient age was 52 years. The sensitivity of PET in detecting axillary metastases was 28%, and the specificity was 86%. At diagnosis, 5% of patients were diagnosed with distant metastases. In patients undergoing PET scanning because of suspected recurrence, the sensitivity and specificity for detecting recurrence were 89% and 88%, respectively. Distant metastases were demonstrated in 30% of patients who were thought only to have local-regional recurrence. The results suggest that there are two clinical situations in which PET appears to be particularly valuable. The first is in the evaluation of patients who are suspected of having a tumor recurrence. The other is in identifying patients with multifocal or distant sites of malignancy who otherwise appear to have an isolated, potentially curable, local-regional recurrence.     

Positron emission tomography in non-medullary thyroid cancer

While iodine scanning is the mainstay of functional imaging in differentiated thyroid cancer, there is now a significant body of literature regarding positron emission tomography with 2-fluoro-2-deoxy glucose in thyroid cancer. This clinical review will examine the evidence supporting the use of 2-fluoro-2-deoxy glucose-positron emission tomography throughout the diagnosis and management of thyroid cancer, and provide suggestions for its clinical use and potential future roles.     

Value of fluorodeoxyglucose positron emission tomography in characterizing clinically‐significant thyroid carcinomas

Background: Despite the rising incidence of thyroid incidentalomas, their clinical significance remains unclear. The present study aimed to determine whether fluorodeoxyglucose positron emission tomography (FDG‐PET) is associated with a significantly higher risk of clinically‐significant thyroid carcinoma (CSC) in incidentalomas than other non‐functional imaging modalities. Methods: Over a 2‐year period, 89 patients were identified as having a thyroid incidentaloma. All patients had either surgery or fine needle aspiration cytology (FNAC) with a 12‐month follow up to confirm the nature of the incidentaloma. Surgery was carried out for nodules with malignant or indeterminate FNAC result, or those with in a retrosternal location, with size > 4 cm or local symptoms. Results: A total of 21 (23.6%) patients had their incidentaloma detected by FDG‐PET (PET group) and 68 (76.4%) by non‐PET imaging modalities (non‐PET group). Differentiated thyroid carcinoma was confirmed in 18 (20.2%) patients. The rate of malignancy was 61.9% in the PET group and 7.4% in the non‐PET group (P = 0.001). After excluding the occult microcarcinomas, the risk of malignancy reduced to 14.6%, but the difference in malignancy rate became more marked between the PET and non‐PET group (42.9% vs 2.9%, P = 0.001). The maximum standardized uptake value on FDG‐PET was similar between benign and malignant lesions (P = 0.124). Conclusion: The overall risk of CSC in thyroid incidentalomas was 14.6%. Those detected by FDG‐PET were significantly more likely to harbour CSC than those by non‐functional modalities. Incidentalomas with focal FDG uptake should be thoroughly investigated with USG and FNAC.     

Peritoneal recurrence of colon cancer detected by positron emission tomography: Report of a case

Increased glucose metabolism has been reported to occur in association with colorectal cancer. As positron emission tomography (PET) using [¹⁸F]fluorodeoxyglucose is able to depict hypermetabolic sites, it can therefore be used to detect colorectal cancer. A 69-year-old male patient with a recurrent solitary liver metastasis from colon cancer underwent whole-body PET which revealed high [¹⁸F]fluorodeoxyglucose uptake in the lesion. Furthermore, PET revealed peritoneal metastases that had not been detected by conventional imaging methods. Consequently, PET proved useful in helping us to avoid performing unnecessary treatment for the liver metastasis. Although it is uncertain whether early identification of recurrence can prolong survival, it may help to prevent unnecessary treatments being carried out. Thus, the application of PET in carefully selected patients could be beneficial to the management of recurrent colorectal cancer.     

Positron‐emission tomography/computed tomography (PET/CT) in the initial staging of primary rectal cancer

Objective The aim of this study was to assess the role of ¹⁸flourodeoxyglucose positron‐emission tomography/computed tomography (PET/CT) in the initial staging of primary rectal adenocarcinoma. Method A total of 20 patients with adenocarcinoma of the rectum were assessed with both PET/CT and conventional staging (CT chest/abdomen/pelvis, MRI rectum). Discordance with conventional imaging and incidental findings on PET were recorded and the patients presented to a colorectal cancer multidisciplinary team to assess management changes. Patients were followed up so that discordant or incidental findings could be verified by intra‐operative examination, imaging or histology where possible. Results Positron‐emission tomography/computed tomography correctly identified the primary tumour in all 20 patients. Comparing PET/CT with conventional staging modalities, there were 11 discordant or incidental findings in nine patients (45%). This resulted in a potential change in stage in 30% (four patients downstaged and two upstaged). PET/CT suggested additional neoplastic pathology in three patients and excluded the same in two patients. The incidental neoplastic findings were of minor clinical significance and one was eventually deemed false positive. While PET/CT resulted in potential management changes in five patients (25%), no changes in surgical management occurred. When tumours were grouped according to conventional stage, PET/CT resulted in fewer changes in stage in stage I (0%), compared with stages II to IV (43%) (P = 0.08). Conclusion Positron‐emission tomography/computed tomography provides additional information to conventional staging in primary rectal cancer. This information produced minor management changes in this study and did not effect surgical management. PET/CT may be most appropriately used selectively in more advanced stages and where indeterminate findings exist with conventional staging.     

The use of positron emission tomography in detecting hepatoblastoma recurrence--a cautionary tale

Purpose

The use of positron emission tomography (PET) with [18F] fluorodeoxyglucose (FDG) in the detection of recurrences has been well established in many tumor types. Here the authors present their experience using this modality in the evaluation of posttreatment hepatoblastoma patients.

Methods

The authors conducted a retrospective review on patients with hepatoblastoma diagnosed from 1996 to 2003. FDG-PET imaging was performed together with measurement of alpha-fetal protein (AFP) during posttreatment follow-up.

Results

Sixteen patients (8 boys and 8 girls) were identified in this series. The mean age was 23.5 months (range, 5 months to 4 years). Three posttreatment patients had PET results suggestive of tumor recurrence. One of these patients had normal AFP level and suspected recurrence in the caudate lobe. Radiologic-guided biopsy was performed 3 times, and there was no evidence of tumor. The other 2 patients underwent further liver resections because of mildly raised AFP levels. The histology of these showed regenerative liver tissue only with no hepatoblastoma recurrence.

Conclusions

Although PET has been gaining popularity as a tool in the detection of tumor recurrences worldwide, it has been shown in this series that PET may not be useful in hepatoblastoma patients, and caution must be taken in the interpretation of positive results.     

Impact of F18-fluorodeoxyglycose positron emission tomography/computed tomography on the management of resectable pancreatic tumours

Background: Positron emission tomography/computed tomography (PET/CT) using F18‐fluorodeoxyglucose has been shown to be valuable in the management of malignant disease. The aim of this study is to investigate the impact of this technique on the management of patients with resectable pancreatic tumours. Methods: Thirty‐six patients with 37 potentially resectable pancreatic tumours on diagnostic CT imaging underwent PET/CT scans. Operative findings, histological reports and/or clinical follow‐up served as standard of reference. The impact of PET/CT on patient management was estimated by calculating the percentage of patients whose treatment plan was altered due to PET/CT. Results: Pancreatic adenocarcinoma was diagnosed in 30 patients, neuroendocrine tumours in 3, mass‐forming pancreatitis in 3 and serous cystadenoma in 1. The median standard uptake (max) value was 5.0 (range 2.2–12.0). Sensitivity and specificity of detecting extrapancreatic metastatic disease were 73% and 100%, respectively. Three occult liver metastases were detected at laparotomy following negative PET/CT. PET/CT findings influenced the management of 8 (22%) patients – 3 with liver metastases, 3 with bone metastases, 1 with lymph node metastases and 1 by identifying the benign appearance of the pancreatic tumour. Conclusion: PET/CT achieves a significant diagnostic impact in detecting extrapancreatic metastatic disease. F18‐fluorodeoxyglucose PET/CT appears to be useful in assessing suspicious pancreatic masses.     

Assessment of residual liver functional reserve after portal embolization with positron emission tomography usingl-[methyl-11C] methionine and computed tomography

Hepatic functional reserve after portal embolization was assessed in eight patients according to the functional volume index (FVI), a new index obtained using positron emission tomography (PET) withl-[methyl-¹¹C] methionine. FVI in residual liver was 1744–5252 (mean, 3441) (normal range, 3106–6211) before percutaneous transhepatic portal embolization (PTPE) and 2457–6906 (mean, 4590) after PTPE. FVI exceeded 4000 in five patients and did not reach 4000 in three patients after PTPE. Two patients with FVI values of more than 4000 survived after hepatectomy and one with FVI under 4000 died of liver failure. FVI is a useful criterion for determining indications for PTPE; a value exceeding 4000 is needed before major hepatectomy can be safely performed after PTPE.     

氟脱氧葡萄糖和乙酸盐联合在正电子发射型计算机体层显像诊断肝细胞癌的效能：Meta分析

目的通过meta分析的方法,系统评价^11F—FDG和^11C—Acetate正电子发射型计算机体层扫描联合诊断肝细胞癌的效能。方法使用相关检索词对Medline Pubmed和中国知识基础设施数字图书馆（CNKI）进行检索,收集近年来公开发表的相关中英文文献,并对纳入文献质量进行评分,提取纳入文献的研究数据进行meta分析。结果共有5篇文献纳入本次meta分析。其中英文4篇。中文1篇;对纳入文献进行质量评分,文献得分占总分的78．8％,两种正电子药物联合显像对肝细胞癌的显示率可达到82．9％;肿瘤直径小于2cm、2.5cm之间及5cm以上的肝细胞癌FDG显示阳性率为25％、45．9％、80．9％,Acetate为79．2％、80．1％、78．7％;1、2级分化的肝细胞癌,FDG显示阳性率为48％,Acetate为73．3％;3、4级分化的肝细胞癌,FDG显示阳性率为89．5％,Acetate为86．8％;肝功能Child A级时,FDG显示肝细胞癌的阳性率为59％,Acetate为72％。结论Acetate和FDGPET对肝细胞癌显像有重要的补充作用,二者联合能提高肝细胞癌的显像效能。